Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

Background Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. Objectives To utilize data collected in a French investigator-initi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of dermatology (1951) 2019-08, Vol.182, p.1111-1119
Hauptverfasser: Chen, D M, Odueyungbo, A, Csinady, E, Gearhart, L, Lehane, P, Cheu, M, Maho‐vaillant, M, Prost‐squarcioni, C, Hebert, V, Houivet, E, Calbo, S, Caillot, F, Golinski, M L, Labeille, B, Picard‐dahan, C, Paul, C, Richard, M A, Bouaziz, J D, Duvert‐lehembre, S, Bernard, P, Caux, F, Alexandre, M, Ingen‐housz‐oro, S, Vabres, P, Delaporte, E, Quereux, G, Dupuy, A, Debarbieux, S, Avenel‐audran, M, d'Incan, M, Bedane, C, Bénéton, N, Jullien, D, Dupin, N, Misery, L, Machet, L, Beylot‐barry, M, Dereure, O, Sassolas, B, Benichou, J, Musette, P, Joly, P
Format: Artikel
Sprache:eng
Schlagworte:
Human health and pathology
Immunology
Life Sciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. Objectives To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV.
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.18482